Until recently, genomics was a "read-only" science, but scientists have developed a tool for quick and easy deletion of DNA in living cells. This software, published in PLOS Computational Biology, will boost efforts to understand the vast regions of non-coding DNA, or "Dark Matter", in our DNA and may lead to discovery of new disease-causing genes and potential new drugs.
CRISPR-Cas9 is a revolutionary technique for editing genomes and until recently, most studies employing it were aimed at silencing protein-coding genes, the best-studied part of our genome. However our genome consists of 99% of DNA that does not encode any protein. Often described as the "Dark Matter" of the genome, this "non-coding DNA" is recognised to be crucially important for understanding all aspects of human biology, including disease and evolution.
The Johnson lab recently created a tool based on CRISPR-Cas9, called "DECKO", which can be used to delete any desired piece of non-coding DNA. The unique advantage of DECKO is that it uses two individual sgRNAs, acting like two "molecular scissors" that snip out a piece of DNA. The approach was widely adopted, but as no software was available for designing the pairs of sgRNAs that are required, designing deletion experiments was time-consuming.
In response to this, the researchers in this study led by Carlos Pulido, created a software pipeline called CRISPETa, a flexible solution for designing CRISPR deletion experiments. The user tells CRISPETa what region they wish to delete, and the software returns a set of optimised pairs of sgRNAs that can directly be used by experimental researchers. One of the key features is that it can create designs at high scales, with future screening experiments in mind.
The researchers showed that CRISPETa designs efficiently delete their desired targets in human cells. Most importantly, in those regions that give rise to RNA molecules, the researchers showed that the RNA molecules also carry the deletion.
"Ultimately, we expect that CRISPR deletion and other genome engineering tools to lead to a revolution in our ability to understand the genomic basis of disease, particularly in the 99% of DNA that does not encode proteins. Apart from being used as a basic research tool, CRISPR may even be used in the future as a powerful therapeutic to reverse disease-causing mutations," adds Rory Johnson.
CRISPETa is designed for use by non-experts so that it can be useful for scientific researchers, from even the most modest experimental laboratory. These users may, for example, delete a suspected functional region of non-coding DNA, and test the outcome on cellular or molecular activity. This software will also be potentially valuable for groups aiming to utilise CRISPR deletion for therapeutic purposes, by for example, deleting a region of non-coding DNA that is suspected to cause a disease state.
"We hope that this new software tool will allow the greatest possible number of researchers to harness the power of CRISPR deletion in their research," says Carlos Pulido, the student who wrote the CRISPETa software.
This press release is based on text provided by the authors.
In your coverage please use this URL to provide access to the freely available article in PLOS Computational Biology:
Citation: Pulido-Quetglas C, Aparicio-Prat E, Arnan C, Polidori T, Hermoso T, Palumbo E, et al. (2017) Scalable Design of Paired CRISPR Guide RNAs for Genomic Deletion. PLoS Comput Biol 13(3): e1005341. doi:10.1371/journal.pcbi.1005341
Funding: This work was financially supported by the following grants: CSD2007-00050 from the Spanish Ministry of Science, grant SGR-1430 from the Catalan Government, grant ERC-2011-AdG-294653-RNA-MAPS from the European Community financial support under the FP7 and grant R01MH101814 by the National Human Genome Research Institute of the National Institutes of Health, to RG. Ramón y Cajal RYC-2011-08851 and Plan Nacional BIO2011-27220, both from the Spanish Ministry of Science, to RJ. We also acknowledge support of the Spanish Ministry of Economy and Competitiveness, 'Centro de Excelencia Severo Ochoa 2013-2017', SEV-2012-0208. We also acknowledge the support of the CERCA Programme / Generalitat de Catalunya. This research was partly supported by the NCCR RNA & Disease funded by the Swiss National Science Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.